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Pathogens have adapted to a variety of
constantly changing environments in order
to survive. Doctors, pharmaceutical com-
panies, and scientists are faced with the
challenge of learning how to combat these
pathogens and protect us before they can
infect us.
Several obstacles prevent us from be-
coming  completely  immune  to  various
pathogens. First, many bacteria and viruses
have evolved resistance to drugs. Second,
we still do not know as much as we should
about the mechanisms that parasites, bac-
teria, and viruses use to infect us, how they
cause disease, or how our bodies react to
infections. 
Pharmaceutical companies invest bil-
lions of dollars every year in attempt to de-
velop drugs to target these pathogens or
lessen their symptoms to help patients live
more comfortable lives. Governments and
private  foundations  also  invest  a  lot  of
money  in  research  to  learn  more  about
these  evolving  pathogens  and  help  find
“weak spots” in the parasites, bacteria, and
viruses for the pharmaceutical companies
to target.
In this special issue of the Yale Jour-
nal of Biology and Medicine, “Combating
Evolving Pathogens,” we take a look at a
variety of pathogens known to cause infec-
tious diseases so we can learn about them
as well as the current methods available to
treat infected patients. The pathogens dis-
cussed include parasites (soil transmitted
helminths (STHs), Plasmodium species),
viruses  (respiratory  syncytial  virus,  in-
fluenza, human metapneumovirus, human
bocavirus, and HIV), bacteria (Mycobac-
terium tuberculosis, Salmonella, and me-
thicillin-resistant Staphylococcus aureus). 
Bath et al. conducted a survey in the
Manikganj district in Bangladesh on the
community’s  understanding  and  knowl-
edge of treatment and prevention of STHs
(more  commonly  known  as  intestinal
worms). Approximately one billion of the
world’s population is infected with STHs.
This has led to a number of outreach pro-
grams being developed to help educate and
treat those with these infections. The results
of the survey indicate that although many
people within this rural and poorly edu-
cated community understood how STHs
are transmitted, they took very few steps, if
any, to prevent transmission. 
Sadanand discusses yet another well-
known species of parasite, Plasmodium,
that causes malaria. She fills us in on what
is known about the pathogenesis of malaria,
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fection. Finally, she discusses the current
methods available for diagnosing malaria
and the methods available to reduce infec-
tion through either drug treatment or prac-
tices that reduce the number of mosquitoes
that can pass on this pathogen.
With the technologies we have at hand,
scientists  have  begun  uncovering  new
viruses that cause illnesses previously not
believed to be caused by pathogens. Hustedt
and Vazquez have focused on pediatric res-
piratory tract infections caused by many
viruses, such as respiratory syncytial virus
and influenza, as well as two newly discov-
ered viruses: human metapneumovirus and
human bocavirus. They describe a number
of methods that can be used to identify the
virus causing infection and thus enable doc-
tors to better treat their patients. Stansell and
Desrosiers provide a different perspective
into human immunodeficiency virus (HIV),
which is the causative agent of acquired im-
mune deficiency syndrome (AIDS). They
discuss how glycoproteins found on the sur-
face of the HIV virion are used to prevent
more important viral epitopes from being at-
tacked by the immune system. Carbohy-
drates that make up the glycoproteins have
evolved to help the virus spread throughout
the organism it infects as well as modulate
the cytokines made by the host. Further un-
derstanding these viral surface glycoproteins
allows a novel target for drugs in order to
decrease the deleterious effects of HIV in-
fection.
Vaccines help keep patients from be-
coming  infected  by  various  pathogens.
Thaiss  and  Kaufman  discuss  the  current
work being done to develop a new vaccine
against tuberculosis (TB). TB causes ap-
proximately two million deaths each year
and mainly affects those in developing re-
gions of the world. Many of us are familiar
with the Bacille Calmette-Guérin (BCG)
vaccine that has been used for decades to
protect against severe childhood TB. How-
ever, this does not protect against adult pul-
monary  disease.  Thaiss  and  Kaufman
discuss and describe the current vaccine can-
didates available as well as explain the many
obstacles that a new vaccine will have to
overcome.
Carleton provides insight into how we
can now manipulate many pathogenic bac-
teria to use them as vaccine vectors, empha-
sizing  how  far  we  have  come  in  our
understanding of bacteria such as Salmo-
nella and how technologies have evolved to
help us make use of natural pathogens for
our own advantages.
Balkin  and  Morell  discuss  the  well-
known  superbug  methicillin-resistant
Staphylococcus  aureus (MRSA),  how  it
came to be, and how it is able to spread
throughout hospitals as well as the commu-
nity. They discuss current efforts to gener-
ate new antibiotics against MRSA.
Noblin and Brahme’s interview with
Dr. Mark Cockett, Vice President of Infec-
tious Diseases and Applied Genomics at
Bristol-Myers Squibb (BMS), completes the
issue. Cockett’s department focuses on tar-
geting HIV, hepatitis B, and hepatitis C.
Cockett informs us how BMS decides which
pathogen to target for drug development, the
benefits and downfall of high-throughput
screening to identify potential compounds
that could be developed into drugs, and the
role that academia can play in aiding drug
discovery and development.
The aim of this special issue is to learn
more about how pathogens are constantly
evolving and the battle that we have ahead
of us to learn how to overcome these deadly
pathogens.
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